Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Allogeneic transplantation in CTCL

Rudolf Stadler • 15 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases

Rudolf Stadler, MD, PhD, University Medical Center Minden, Minden, Germany, gives an overview of the role of transplantation in the treatment of cutaneous T-cell lymphoma (CTCL), describing its use in clinical practice for patients within a certain age bracket and with advanced disease. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Rudolf Stadler

1:25
PARCT: atezolizumab for CTCL and next steps
Rudolf Stadler • 15 Oct 2021
1:23
RESMAIN: HDAC inhibitor resminostat for CTCL
Rudolf Stadler • 15 Oct 2021
1:27
Lacutamab for CTCL
Rudolf Stadler • 15 Oct 2021
1:15
Advances in understanding the molecular pathogenesis of CTCL
Rudolf Stadler • 15 Oct 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals